157 related articles for article (PubMed ID: 17559682)
1. Modeling the effect of levothyroxine therapy on bone mass density in postmenopausal women: a different approach leads to new inference.
Mohammadi B; Haghpanah V; Tavangar SM; Larijani B
Theor Biol Med Model; 2007 Jun; 4():23. PubMed ID: 17559682
[TBL] [Abstract][Full Text] [Related]
2. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
3. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
Jódar E; Begoña López M; García L; Rigopoulou D; Martínez G; Hawkins F
Osteoporos Int; 1998; 8(4):311-6. PubMed ID: 10024900
[TBL] [Abstract][Full Text] [Related]
4. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
[TBL] [Abstract][Full Text] [Related]
5. [Bone mineral density in patients on long-term therapy with levothyroxine].
Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
[TBL] [Abstract][Full Text] [Related]
6. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
[TBL] [Abstract][Full Text] [Related]
7. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis.
Franklyn JA; Betteridge J; Holder R; Sheppard MC
Thyroid; 1995 Oct; 5(5):359-63. PubMed ID: 8563472
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre.
De Rosa G; Testa A; Giacomini D; Carrozza C; Astazi P; Caradonna P
Clin Endocrinol (Oxf); 1997 Nov; 47(5):529-35. PubMed ID: 9425392
[TBL] [Abstract][Full Text] [Related]
9. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
[TBL] [Abstract][Full Text] [Related]
10. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women.
Kung AW; Lorentz T; Tam SC
Clin Endocrinol (Oxf); 1993 Nov; 39(5):535-40. PubMed ID: 8252741
[TBL] [Abstract][Full Text] [Related]
11. Global skeletal uptake of technetium-99m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancer.
Frusciante V; Carnevale V; Scillitani A; Zingrillo M; Dicembrino F; Giannatempo GM; Ghiggi MR; Minisola S
Eur J Nucl Med; 1998 Feb; 25(2):139-43. PubMed ID: 9473261
[TBL] [Abstract][Full Text] [Related]
12. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
Marcocci C; Golia F; Bruno-Bossio G; Vignali E; Pinchera A
J Clin Endocrinol Metab; 1994 Apr; 78(4):818-23. PubMed ID: 8157704
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of bone density in women after thyroid cancer surgery and treatment with suppressive doses of L-thyroxine].
Jurecka-Tuleja B; August R; Kukulska A; Bartnikowa W; Deja R; Czernik E; Handkiewicz-Junak D
Wiad Lek; 2001; 54 Suppl 1():378-82. PubMed ID: 12182053
[TBL] [Abstract][Full Text] [Related]
15. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Sijanovic S; Karner I
Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
[TBL] [Abstract][Full Text] [Related]
16. Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis.
Hawkins F; Rigopoulou D; Papapietro K; Lopez MB
Calcif Tissue Int; 1994 Jan; 54(1):16-9. PubMed ID: 8118747
[TBL] [Abstract][Full Text] [Related]
17. Effects of thyroxine therapy on bone metabolism in postmenopausal women with hypothyroidism.
Affinito P; Sorrentino C; Farace MJ; di Carlo C; Moccia G; Canciello P; Palomba S; Nappi C
Acta Obstet Gynecol Scand; 1996 Oct; 75(9):843-8. PubMed ID: 8931510
[TBL] [Abstract][Full Text] [Related]
18. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study.
Ross DS
Am J Med; 1993 Oct; 95(4):385-8. PubMed ID: 8213870
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy.
Nuzzo V; Lupoli G; Esposito Del Puente A; Rampone E; Carpinelli A; Del Puente AE; Oriente P
Gynecol Endocrinol; 1998 Oct; 12(5):333-7. PubMed ID: 9859026
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Bone Mineral Density Using DXA and cQCT in Postmenopausal Patients Under Thyrotropin Suppressive Therapy.
Kim K; Kim IJ; Pak K; Kim SJ; Shin S; Kim BH; Kim SS; Lee BJ; Jeon YK
J Clin Endocrinol Metab; 2018 Nov; 103(11):4232-4240. PubMed ID: 29982711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
